Cognetivity Neurosciences (CSE: CGN) this morning announced the expansion of an ongoing study in the UK related to its cognitive testing platform. The expansion will enable the iPad-based integrated cognitive assessment to be conducted remotely for the study, enabling participants to participate in the study from home, removing the risk of exposure to COVID-19.
The study being conducted was originally launched last January as a means of investigating the ability of the cognitive assessment to drive improvements in dementia care pathways within the United Kingdom’s National Health Service. Referred to as ADePT, or Accelerating Dementia Pathway Technologies, the project is a collaboration with the Sussex Partnership NHS Trust and Alzheimer’s Research UK.
To date the study had seen participants take the integrated cognitive assessment in person at NHS facilities. With the latest expansion of the program however, the study has advanced to the point where the assessment can be taken remotely, as is the ultimate goal of the platform. The added benefit for participants is that they are no longer required to attend a hospital, where there is a heightened risk of contracting COVID-19.
“Cognetivity’s ICA provides a much-needed cognitive assessment platform, where patients at home can remotely undertake a more thorough assessment. Currently specialist clinicians are finding virtual assessments challenging, and this challenge is even more acute in primary care due to overwhelming demands on doctors’ time during this pandemic. An effective assessment tool which can inform colleagues’ views about referrals to Memory Assessment Clinics without the need for face to face consultation is very timely.”
Dr Naji Tabet, Sussex Partnership NHS Trust Consultant & Chief Investigator
Cognetivity Neurosciences last traded at $0.59 on the CSE.
Sponsored · Mercado Minerals
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
